Key Takeaways
- Tyson Foods (TSN) reported Q3 2026 adjusted EPS of $0.99, surpassing analyst estimates of $0.97, despite a slight revenue miss at $13.87 billion.
- Eli Lilly (LLY) received FDA Breakthrough Therapy designation for its drug olomorasib, targeting a specific mutation in advanced pancreatic cancer.
- UK Prime Minister Andy Burnham is reportedly considering a fresh King’s Speech to redefine his government's legislative priorities following his recent appointment.
- The European Commission has urged Spain to strengthen its borders following a tragic migrant surge in the enclave of Ceuta that resulted in at least 67 deaths.
- Tyson Foods maintained its full-year outlook, projecting sales growth of 2.5% to 3.5% and adjusted operating income between $2.1 billion and $2.3 billion.
Tyson Foods Navigates Mixed Q3 Results
Tyson Foods (TSN) delivered a resilient third quarter for fiscal 2026, posting an adjusted EPS of $0.99, which beat the consensus estimate of $0.97. However, quarterly revenue of $13.87 billion fell short of the $14.1 billion anticipated by Wall Street. The company’s performance was bolstered by its Chicken and Prepared Foods segments, which helped offset ongoing challenges in the Beef segment caused by a difficult cattle cycle.
Management updated its capital expenditure guidance, now expecting $700 million to $900 million for the fiscal year, a tightening from the previous range of $700 million to $1 billion. Tyson continues to project full-year sales growth of 2.5% to 3.5% and expects net interest expenses to remain around $365 million. Investors are closely monitoring the company's ability to maintain margins amidst fluctuating protein prices and operational costs.
Eli Lilly Gains Momentum in Oncology
Eli Lilly and Company (LLY) announced today that the U.S. FDA has granted Breakthrough Therapy status to olomorasib (LY3537982). This designation is specifically for the treatment of adult patients with KRAS G12C-mutant advanced pancreatic cancer who have previously undergone systemic therapy. This marks the second such designation for the oral inhibitor, which is also being studied for lung cancer.
The FDA's decision was based on preliminary data from the Phase 1/2 LOXO-RAS-20001 study, which showed promising clinical activity in a disease area with a five-year survival rate of less than 5%. The breakthrough status is expected to expedite the development and regulatory review process, potentially bringing a first-of-its-kind targeted therapy to pancreatic cancer patients sooner.
Geopolitical Shifts in the UK and EU
In the United Kingdom, reports from the iPaper suggest that Prime Minister Andy Burnham may hold a second King’s Speech later this year. This move would allow the new administration to formalize its "10-year plan" and pivot legislative focus toward cost-of-living relief and regional devolution. Burnham, who recently succeeded Keir Starmer, has pledged the "biggest changes in 40 years" to the British economic model.
Concurrently, European Commission President Ursula von der Leyen sent a formal letter to Spanish Prime Minister Pedro Sanchez emphasizing that the EU "must do more to strengthen the borders." The communication follows a massive migration event in Ceuta, where approximately 60,000 people attempted to cross from Morocco in late July. The Commission has pledged enhanced technical and financial support to Morocco and Spain to improve early-warning systems and border management.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.